These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 33826790)

  • 21. Comparison of HPV-16 and HPV-18 Genotyping and Cytological Testing as Triage Testing Within Human Papillomavirus-Based Screening in Mexico.
    Torres-Ibarra L; Cuzick J; Lorincz AT; Spiegelman D; Lazcano-Ponce E; Franco EL; Moscicki AB; Mahmud SM; Wheeler CM; Rivera-Paredez B; Hernández-López R; León-Maldonado L; Salmerón J;
    JAMA Netw Open; 2019 Nov; 2(11):e1915781. PubMed ID: 31747033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p16/Ki67 dual stain triage versus cytology in primary human papillomavirus-based cervical cancer screening with limited genotyping.
    Trzeszcz M; Mazurec M; Jach R; Mazurec K; Kotkowska-Szeps I; Kania M; Wantuchowicz M; Wasowska J; Duczek-Polakiewicz M; Rozmus P; Streb J; Halon A
    J Med Virol; 2023 Nov; 95(11):e29271. PubMed ID: 38009626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meta-analysis of the accuracy of p16 or p16/Ki-67 immunocytochemistry versus HPV testing for the detection of CIN2+/CIN3+ in triage of women with minor abnormal cytology.
    Peeters E; Wentzensen N; Bergeron C; Arbyn M
    Cancer Cytopathol; 2019 Mar; 127(3):169-180. PubMed ID: 30811902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
    Canfell K; Saville M; Caruana M; Gebski V; Darlington-Brown J; Brotherton J; Heley S; Castle PE
    BMJ Open; 2018 Jan; 8(1):e016700. PubMed ID: 29374658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection Rate of High-Grade Cervical Neoplasia and Cost-Effectiveness of High-Risk Human Papillomavirus Genotyping with Reflex Liquid-based Cytology in Cervical Cancer Screening.
    Tay SK; Lin LE; Goh RC
    Ann Acad Med Singap; 2017 Jul; 46(7):267-273. PubMed ID: 28821890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.
    Uijterwaal MH; Polman NJ; Witte BI; van Kemenade FJ; Rijkaart D; Berkhof J; Balfoort-van der Meij GA; Ridder R; Snijders PJ; Meijer CJ
    Int J Cancer; 2015 May; 136(10):2361-8. PubMed ID: 25345358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Health technology assessment report. Use of liquid-based cytology for cervical cancer precursors screening].
    Ronco G; Confortini M; Maccallini V; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(5 Suppl 2):e1-e33. PubMed ID: 23139163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance of p16INK4a/Ki-67 immunocytochemistry for identifying CIN2+ in atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesion specimens: a Japanese Gynecologic Oncology Group study.
    Fujii T; Saito M; Hasegawa T; Iwata T; Kuramoto H; Kubushiro K; Ohmura M; Ochiai K; Arai H; Sakamoto M; Motoyama T; Aoki D
    Int J Clin Oncol; 2015 Feb; 20(1):134-42. PubMed ID: 24744261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology.
    Agorastos T; Chatzistamatiou K; Katsamagkas T; Koliopoulos G; Daponte A; Constantinidis T; Constantinidis TC;
    PLoS One; 2015; 10(3):e0119755. PubMed ID: 25793281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cervical Precancer and Cancer Risk by Human Papillomavirus Status and Cytologic Interpretation: Implications for Risk-Based Management.
    Castle PE; Aslam S; Behrens C
    Cancer Epidemiol Biomarkers Prev; 2016 Dec; 25(12):1595-1599. PubMed ID: 27587789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunostaining of p16(INK4a)/Ki-67 and L1 capsid protein on liquid-based cytology specimens obtained from ASC-H and LSIL-H cases.
    Byun SW; Lee A; Kim S; Choi YJ; Lee YS; Park JS
    Int J Med Sci; 2013; 10(12):1602-7. PubMed ID: 24151431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of high-performance human papillomavirus testing to improve cervical cancer screening in China: a prospective population-based multicentre cohort study.
    Yin J; Zhang S; Li Z; Li Y; Wang H; Zhang X; Pan Q; Chen W; Luo X; Sun X; Zhao F; Qiao Y
    Clin Microbiol Infect; 2024 Sep; 30(9):1190-1196. PubMed ID: 38599463
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-risk human papillomavirus DNA test and p16(INK4a) in the triage of LSIL: a prospective diagnostic study.
    Tsoumpou I; Valasoulis G; Founta C; Kyrgiou M; Nasioutziki M; Daponte A; Koliopoulos G; Malamou-Mitsi V; Karakitsos P; Paraskevaidis E
    Gynecol Oncol; 2011 Apr; 121(1):49-53. PubMed ID: 21194734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Performance of HPV16/18 in Triage of Cytological Atypical Squamous Cells of Undetermined Significance.
    Cao X; Liu S; Jia M; Chen H; Zhao D; Dong B; Guo Z; Ren L; Zhang S; Sun X
    Anal Cell Pathol (Amst); 2019; 2019():4324710. PubMed ID: 31934532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method.
    Zhao FH; Lewkowitz AK; Chen F; Lin MJ; Hu SY; Zhang X; Pan QJ; Ma JF; Niyazi M; Li CQ; Li SM; Smith JS; Belinson JL; Qiao YL; Castle PE
    J Natl Cancer Inst; 2012 Feb; 104(3):178-88. PubMed ID: 22271765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Performance of HPV Genotyping Combined with p16/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women.
    Jiang MY; Wu Z; Li T; Yu L; Zhang SK; Zhang X; Qu P; Sun P; Xi MR; Liu X; Liao G; Sun L; Zhang Y; Chen W; Qiao YL
    Cancer Prev Res (Phila); 2020 Feb; 13(2):163-172. PubMed ID: 31871224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status].
    Luo HX; Du H; Liu ZH; Zhang LJ; Wang C; Wu RF
    Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):232-238. PubMed ID: 29575846
    [No Abstract]   [Full Text] [Related]  

  • 38. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interpretation of p16(INK4a) /Ki-67 dual immunostaining for the triage of human papillomavirus-positive women by experts and nonexperts in cervical cytology.
    Allia E; Ronco G; Coccia A; Luparia P; Macrì L; Fiorito C; Maletta F; Deambrogio C; Tunesi S; De Marco L; Gillio-Tos A; Sapino A; Ghiringhello B
    Cancer Cytopathol; 2015 Apr; 123(4):212-8. PubMed ID: 25534957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial.
    Wright TC; Behrens CM; Ranger-Moore J; Rehm S; Sharma A; Stoler MH; Ridder R
    Gynecol Oncol; 2017 Jan; 144(1):51-56. PubMed ID: 28094038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.